Eos 002

Drug Profile

Eos 002

Alternative Names: Eos-002

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eos Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ERBB-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 13 Sep 2017 Eos 002 is covered by patent protection in USA and US PTO grants patent for Eos 002 for Breast Cancer
  • 13 Sep 2017 Preclinical trials in Solid tumours (Diagnosis) in USA (IV)
  • 13 Sep 2017 Preclinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top